Dyne Therapeutics Inc. (DYN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Dyne Therapeutics Inc May Have Committed Securities Fraud And The Schall Law Firm Encourages Shareholders To Partake In An Inquiry
LOS ANGELES, CA / ACCESSWIRE / September 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Lost Money on Dyne Therapeutics, Inc.(DYN)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / September 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Dyne Therapeutics, Inc. ("Dyne Therapeutics, Inc.") (NASDAQ:DYN) concerning possible violations of federal securities laws. Dyne issued a press release on September 3, 2024, "announc[ing] new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping demonstrating unprecedented dystrophin expression and functional improvement in multiple cohorts.
(DYN) INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Dyne Therapeutics, Inc. and Encourages Investors to Contact the Firm!
NEW YORK CITY, NY / ACCESSWIRE / September 10, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN). Investors who purchased Dyne securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/DYN.
Dyne Therapeutics, Inc. Investigated by Shareholder Rights Advocates – Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - DYN
NEW YORK, NY / ACCESSWIRE / September 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Dyne Therapeutics, Inc. ("Dyne Therapeutics, Inc.") (NASDAQ:DYN) concerning possible violations of federal securities laws. Dyne issued a press release on September 3, 2024, "announc[ing] new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping demonstrating unprecedented dystrophin expression and functional improvement in multiple cohorts.
Dyne Therapeutics, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - DYN
NEW YORK, NY / ACCESSWIRE / September 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Dyne Therapeutics, Inc. ("Dyne Therapeutics, Inc.") (NASDAQ:DYN) concerning possible violations of federal securities laws. Dyne issued a press release on September 3, 2024, "announc[ing] new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping demonstrating unprecedented dystrophin expression and functional improvement in multiple cohorts.
Investors In Dyne Therapeutics, Inc. Are Invited To Join An Investigation For Possible Securities Related Infractions
LOS ANGELES, CA / ACCESSWIRE / September 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Investors who Lost Money on Dyne Therapeutics, Inc. Should Contact Levi & Korsinsky About an Ongoing Investigation - DYN
NEW YORK, NY / ACCESSWIRE / September 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Dyne Therapeutics, Inc. ("Dyne Therapeutics, Inc.") (NASDAQ:DYN) concerning possible violations of federal securities laws. Dyne issued a press release on September 3, 2024, "announc[ing] new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping demonstrating unprecedented dystrophin expression and functional improvement in multiple cohorts.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Dyne Therapeutics, Inc.(DYN) And Encourages Stockholders to Reach Out
NEW YORK CITY, NY / ACCESSWIRE / September 9, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN). Investors who purchased Dyne securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/DYN.
Dyne Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - DYN
NEW YORK, NY / ACCESSWIRE / September 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Dyne Therapeutics, Inc. ("Dyne Therapeutics, Inc.") (NASDAQ:DYN) concerning possible violations of federal securities laws. Dyne issued a press release on September 3, 2024, "announc[ing] new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping demonstrating unprecedented dystrophin expression and functional improvement in multiple cohorts.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Dyne Therapeutics, Inc.(DYN) And Encourages Stockholders to Connect
NEW YORK CITY, NY / ACCESSWIRE / September 8, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN). Investors who purchased Dyne securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/DYN.
Dyne Therapeutics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Dyne Therapeutics, Inc. (DYN)
NEW YORK, NY / ACCESSWIRE / September 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Dyne Therapeutics, Inc. ("Dyne Therapeutics, Inc.") (NASDAQ:DYN) concerning possible violations of federal securities laws. Dyne issued a press release on September 3, 2024, "announc[ing] new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping demonstrating unprecedented dystrophin expression and functional improvement in multiple cohorts.
Dyne Therapeutics Inc May Have Committed Securities Fraud And The Schall Law Firm Seeks Shareholder Participation In An Inquiry
LOS ANGELES, CA / ACCESSWIRE / September 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
